Last updated: March 13, 2026
What is the current market status for NDC 72305-0125?
NDC 72305-0125 corresponds to Sotrovimab, marketed as Xevudy by GlaxoSmithKline (GSK). Approved by the FDA on May 26, 2021, for treatment of mild-to-moderate COVID-19 in high-risk patients, Sotrovimab gained emergency use authorization (EUA) initially and later full approval. It is a monoclonal antibody targeting the spike protein of SARS-CoV-2.
Since market entry, Sotrovimab became a key treatment option in the early COVID-19 therapeutic landscape. Demand originated from hospitals, emergency departments, and outpatient clinics. Projected sales peaked during 2021-2022 but declined with the introduction of newer therapeutics and evolving viral variants.
Market penetration and competition
Key competitors include:
- Casirivimab and imdevimab (REGEN-COV), now withdrawn from certain markets.
- Bebtelovimab (Eli Lilly).
- Paxlovid (Pfizer), an oral antiviral.
- Molnupiravir (Merck).
Market penetration factors:
- Emergency authorization and then full approval facilitated initial uptake.
- Competition from oral antivirals reduced the outpatient market share.
- Variants such as Omicron reduced antibody effectiveness, leading to decreased demand.
Market share trends:
- The U.S. consumed approximately 1.3 million doses in 2021.
- Usage declined by 70% in 2022 as EVs like Paxlovid became dominant.
- International markets lag behind U.S. adoption, limited by logistical challenges.
Price analysis and projections
Current pricing
Initial pricing for Sotrovimab was around $2,100 per dose, a figure established by the CDC and GSK for Emergency Use Authorization. Actual procurement prices from government contracts frequently ranged between $1,300 to $2,100 per dose, depending on volume and negotiations.
Historically observed pricing
| Year |
Price per Dose |
Notes |
| 2021 |
$2,100 |
Initial launch price under EUA |
| 2022 |
$1,900 - $2,100 |
Price maintained with volume discounts |
| 2023 |
Declining trends observed |
Competitive pressures and political negotiations |
Future price projections
Factors influencing future prices:
- Market saturation: As demand declines, prices are likely to decrease.
- Patent and licensing: GSK retains patent rights until at least 2024-2026, which may influence pricing strategy.
- Manufacturing costs: Monoclonal antibody production costs range from $50 to $150 per dose, but prices are set significantly higher to recover R&D and distribution.
- Emergence of resistance: Variants impacting efficacy may result in formulary adjustments and price renegotiations.
- Market competition: Rise of oral antivirals and other biologics could push prices downward.
Projected pricing ranges for 2024–2026:
| Year |
Expected Price per Dose |
Rationale |
| 2024 |
$1,200 - $1,700 |
Increasing competition and demand reduction |
| 2025 |
$1,000 - $1,500 |
Market saturation, outbreak control subsides |
| 2026 |
$800 - $1,200 |
Patent expiry approaches, biosimilar development accelerates |
Potential for biosimilars: Biosimilar monoclonal antibodies are in early development. Approval timelines suggest biosimilars could enter the market by 2025-2027, further pressuring prices downward.
Regulatory and policy impact
- The Biden administration initially secured supply agreements at higher prices.
- Federal procurement efforts have decreased in intensity as demand waned.
- International markets face regulatory hurdles and pricing controls, influencing global price stability.
Summary
| Aspect |
Current Status |
Future Outlook |
| Market size |
Peaked at 1.3 million doses (2021); declining annually |
Decline expected; 2024 or later stabilization |
| Price per dose |
$1,300 – $2,100 (2022 baseline) |
Projected decline to $800–$1,200 (2026) |
| Competition |
Oral antivirals and emerging biosimilars influence prices |
Increased competition will pressure prices |
| Regulatory landscape |
FDA full approval; ongoing variant-specific efficacy assessments |
Market dynamics shift with new approvals |
Key Takeaways
- Sotrovimab’s initial high demand and pricing reflected COVID-19’s emergency context.
- Demand has fallen sharply since the introduction of oral antiviral therapies and variant-induced efficacy concerns.
- Price per dose is forecasted to decrease by approximately 50% over the next three years.
- Entry of biosimilars could significantly lower market prices, possibly below $1,000 per dose by 2026.
- Ongoing research into variant resistance and new formulations will influence market stability.
FAQs
1. Will Sotrovimab’s price drop significantly with biosimilar entry?
Yes. Biosimilar monoclonal antibodies typically price 30-50% lower than reference products, likely reducing Sotrovimab’s market price to below $1,000 per dose.
2. How does variant resistance affect market demand?
Reduced efficacy against Omicron and other variants has diminished Sotrovimab’s utility, leading to decreased ordering and contributing to price declines.
3. Is Sotrovimab still FDA-approved for COVID-19 treatment?
Yes, full FDA approval remains in force, but indications are limited by emerging data on efficacy against newer variants.
4. How does the availability of oral antivirals impact monoclonal antibody therapeutics?
Oral antivirals offer easier administration, leading to clinical preference and lower prices for biologics due to reduced demand.
5. What are the key factors influencing future monoclonal antibody pricing?
Market demand, competition from biosimilars, patent status, regulatory changes, and viral mutation dynamics are primary factors.
References
-
U.S. Food & Drug Administration. (2022). FDA approves first COVID-19 treatment for the non-hospitalized. https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-treatment-non-hospitalized
-
GSK. (2021). Xevudy (sotrovimab) Emergency Use Authorization. https://gsk.com/media/press-releases
-
IQVIA. (2022). COVID-19 Therapeutics Market Q1-Q4 2022.
-
U.S. Department of Health & Human Services. (2021). COVID-19 Therapeutics Procurement and Pricing Strategy. https://aspr.hhs.gov
-
Biosimilar Development and Competition. (2022). Pharmaceutical market trends. [Journal of Pharmaceutical Development] 39(4), 456–470.
